Brief: 3D Medicines Inc Says Envafolimab Supplemental Application Accepted By NMPA
09/02/2026 15:37
Feb 9 (Reuters) - 3D Medicines Inc 1244.HK: ENVAFOLIMAB SUPPLEMENTAL APPLICATION FOR CONDITIONAL-TO-REGULAR APPROVAL TRANSITION ACCEPTED BY NMPA Further company coverage: 1244.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on 3D Medicines
See all newsBrief: 3D Medicines Inc Says Envafolimab Supplemental Application Accepted By NMPA
Brief: 3D Medicines Inc Says Zhang Jing Resigns As CFO
Brief: 3D Medicines Says New Drug Application For First-Line Treatment Of Biliary Tract Cancer Of Envafolimab Accepted
Brief: 3D Medicines Says Envafoimab Granted Orphan Drug Designation
Brief: 3D Medicines Inc Enters Strategic Agreement With Catug Biotechnology